Secondary resistance to immunotherapy associated with β-catenin pathway activation or PTEN loss in metastatic melanoma

Secondary resistance to immunotherapy associated with β-catenin pathway activation or PTEN loss in metastatic melanoma

Abstract Background While cancer immunotherapies including checkpoint blockade antibodies, adoptive T cell therapy, and even some vaccines have given rise to major clinical responses with durability in many cases, a subset of patients who initially respond subsequently develop secondary resistance t...

Full description

Bibliographic Details
Main Authors: Jonathan A. Trujillo, Jason J. Luke, Yuanyuan Zha, Jeremy P. Segal, Lauren L. Ritterhouse, Stefani Spranger, Karen Matijevich, Thomas F. Gajewski
Format: Article
Language:English
Published: BMJ Publishing Group 2019-11-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
Immune checkpoint blockade
Peptide vaccine
Secondary resistance
PTEN-loss
β-Catenin activation
Immune exclusion
Online Access:http://link.springer.com/article/10.1186/s40425-019-0780-0

Internet

http://link.springer.com/article/10.1186/s40425-019-0780-0

Similar Items